Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

seekingalpha.com - Jonathan Block - Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi
Seeking Alpha

Follow us on Google for the latest stock news Royalty Pharma () has acquired from PTC Therapeutics (PTCT) its remaining royalty interest in Roche's (RHHBY) oral spinal muscular atrophy medicine Evrysdi (risdiplam) for $240M plus up to $60M in sales…

thehindu.com - Alok Bhattacharya - What hinders Indian pharma companies from making drugs for rare diseases
What hinders Indian pharma companies from making drugs for rare diseases
The Hindu

Modern healthcare is fundamentally dependent on a constant supply of known and new drugs, making their discovery and manufacture a profitable business. The Indian pharmaceutical industry plays a key role in making drugs available globally at low…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) EVP Sells $786,400.00 in Stock
Royalty Pharma (NASDAQ:RPRX) EVP Sells $786,400.00 in Stock
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the company's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $39.32, for a total transaction of $786,400.00.

marketbeat.com - NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock
MarketBeat

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 26,011 shares of the business's stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $35.68, for a total value…

marketbeat.com - Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock
MarketBeat

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $35.30…

marketbeat.com - Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
MarketBeat

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 75,117 shares of the business's stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a…

marketbeat.com - Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Here's Why
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Here's Why
MarketBeat

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price gapped down before the market opened on Monday. The stock had previously closed at $27.68, but opened at $26.19. Ascentage Pharma Group…

thehindu.com - N. Ravi Kumar - Year Ender 2025: Industries, a mixed bag teaming with hopes
Year Ender 2025: Industries, a mixed bag teaming with hopes
The Hindu

Calendar year 2025 for Telangana from an industries perspective was eventful, marked by several significant, some controversial and arguably a few avoidable developments. At a broad level, the intent to consolidate and attract investments, be it in…

dailymail.co.uk - Natasha Anderson - Sorority girl dies in Christmas Eve accident at family's $4m mansion
Sorority girl dies in Christmas Eve accident at family's $4m mansion
Mail Online

Sign up for our US Editor's Picks newsletter to get all the best exclusive stories The 21-year-old sorority girl daughter of a General Electric executive died on Christmas Eve after a fire caused by 'heat spots' destroyed her family's mansion.

swissinfo.ch - Virginie Mangin - What lies ahead for Switzerland: an economic outlook for 2026
What lies ahead for Switzerland: an economic outlook for 2026
www.swissinfo.ch

The Swiss economy remained stable in 2025 with wage growth and domestic demand offsetting the negative impact of the tariffs imposed on Swiss exports to the United States. Domestic demand is expected to grow 1.4% in 2025 and the unemployment rate…

dailycaller.com - Caden Olson - MTG Vows To Be Crusader Against MAGA World's Fixation With Fake Boobs, Lip Fillers
MTG Vows To Be Crusader Against MAGA World's Fixation With Fake Boobs, Lip Fillers
The Daily Caller

Republican Georgia Rep. Marjorie Taylor Greene said she has always been uncomfortable with what she deemed the “MAGA Mar-a-Lago sexualization” of women and vowed to speak out more on the subject, according to a New York Times…

cnbc.com - Elsa Ohlen - Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient
Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient
CNBC

Novo Nordisk has had a difficult year as investors questioned the company's ability to translate its strides in pioneering GLP-1 drugs to financial gains. Scientists, however, say that Novo's medicine still has potential. What started with a focus…

thehindu.com - Abhinay Deshpande - Gujarat approves Indian AI Research Organisation at GIFT City
Gujarat approves Indian AI Research Organisation at GIFT City
The Hindu

Gujarat Chief Minister Bhupendra Patel on Tuesday (December 30, 2025) granted in-principle approval for the establishment of the Indian AI Research Organisation (IAIRO) to strengthen research and development in artificial intelligence. The proposed…

counterpunch.org - Jeffrey St. Clair - Sound Grammar: the Best Albums of 2025
Sound Grammar: the Best Albums of 2025
Home - CounterPunch.org

ibtimes.co.uk - Shyna Mae Deang - Novo Nordisk's Weight-Loss Vision Impresses Scientists but Tests Investors
Novo Nordisk's Weight-Loss Vision Impresses Scientists but Tests Investors
International Business Times UK

The Danish pharmaceutical giant Novo Nordisk, led by new CEO Maziar Mike Doustdar, is spearheading a radical transformation of its long-term research and development strategy. The company is moving 'beyond the scale' to reposition its flagship…

Receive a Daily briefing on Pharma Industry News

Get Started